NCT04158141 · REGISTRY CONDITION SEARCH

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE3
Status at capture: TERMINATED
Registry last update: 2026-07-13

This trial studies how well the addition of targeted radiation therapy to surgery and the usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural mesothelioma. Targeted radiation therapy such as intensity-modulated radiation therapy or pencil beam scanning uses high energy rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving targeted radiation therapy in addition to surgery and chemotherapy may work better than surgery and chemotherapy alone for the treatment of malignant pleural mesothelioma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Local-failure-free Survival (LFFS)

→

outcome · POSTED

Distant-metastases-free Survival (DMFS)

→

outcome · POSTED

Progression-free Survival (PFS)

→

outcome · POSTED

Number of Patients With Grade 3 or Higher Treatment-related Adverse Event After Randomization

→

outcome · POSTED

Change From Randomization to 9 Months in Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

→

outcome · NOT POSTED

Proportion of Patients With Under-staging, Concordant and Upstaging Between Centrally-reviewed Clinical Staging and Pathologic Staging

→

outcome · NOT POSTED

Association Between Radiation Dose to Gross Residual Disease and Local Control

→

outcome · NOT POSTED

Rate of R0/R1 and R2 Resections, by Type of Procedures (Extended Pleurectomy/Decortication (P/D), P/D and Partial Pleurectomy)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: PRIOR TO STEP 1 REGISTRATION - ALL PATIENTS * Pathologically (histologically or cytologically) confirmed diagnosis of epithelioid or biphasic malignant pleural mesothelioma (MPM) * Imaging proof of clinical stage (American Joint Committee on Cancer \[AJCC\] 8th edition) I-IIIA MPM by PET/CT; * Diagnostic volumetric CT scan of the chest is preferred; however, the CT portion of the PET/CT may be used if CT imaging is of diagnostic quality * MPM is amenable to resection by P/D as determined by a thoracic surgeon * History/physical examination within 42 days prior to Step 1 Registration * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 within 42 days prior to Step 1 Registration * Required Initial Laboratory Values prior to study entry (must be at least 14 days after last infusion of pre-study entry neoadjuvant therapy, if given): * Absolute neutrophil count ≥1500 cells/mm3; * Platelets ≥100,000 cells/mm3; * Hemoglobin ≥ 8.0 g/dL; * Serum total bilirubin ≤ 1.5 X ULN (upper limit of normal); * Aspartate transferase (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) and alanine transaminase (ALT) (serum glutamic-oxaloacetic transaminase (SGPT)) ≤ 3.0 X ULN; * Creatinine clearance ≥45 mL/min by the Cockcroft-Gault (C-G) equation * Negative serum pregnancy test within 14 days of Step 1 Registration for women of childbearing potential * HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Note: HIV testing is not required for eligibility for this protocol. * The patient or a legally authorized representative must provide study-specific informed consent prior to study entry PRIOR TO STEP 1 REGISRATION - PATIENTS WHO RECEIVED SYSTEMIC THERAPY BEFORE STUDY ENTRY * The following systemic therapy and immunotherapy combinations are permissible: 1) cisplatin/carboplatin + pemetrexed; 2) cisplatin/carboplatin + pemetrexed + anti-PD-1/L1 agents; and 3) ipilimumab/nivolumab. * Patients must have received at least 2 cycles of neoadjuvant systemic therapy PRIOR TO STEP 2 RANDOMIZATION - ALL PATIENTS * No evidence of progression as defined by PET/CT within 30 days prior to Step 2 randomization. * Patients must have received at least 2 cycles of systemic therapy and undergone a pleurectomy/decortication with the goal of macroscopic complete resection; * ECOG Performance Status 0-1 within 30 days prior to Step 2 Randomization * History/physical examination within 30 days prior to Step 2 Randomization Exclusion Criteria: PRIOR TO STEP 1 REGISTRATION - ALL PATIENTS * Pregnancy or women who are breastfeeding and unwilling to discontinue. * Participants of childbearing potential (participants who may become pregnant or who may impregnate a partner) unwilling to use highly effective contraceptives during and for six months after end of treatment because the treatment in this study may be significantly teratogenic. * Diagnosis of sarcomatoid mesothelioma * Severe, active co-morbidity defined as follows: * New York Heart Association (NYHA) class III or IV heart failure * Chronic obstructive pulmonary disease (COPD) requiring chronic oral steroid therapy of \> 10 mg prednisone daily or equivalent at the time of registration. Inhaled corticosteroids are allowed; * Unstable angina requiring hospitalization and/or transmural myocardial infarction within the last 3 months; * Interstitial lung disease; * Hemodialysis or peritoneal dialysis; * Concurrent active malignancy (with the exception of current or prior non-melanomatous skin cancer or low-grade malignancies followed observantly for which treatment has not or does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen) * If evidence of disease \< 3 years, institution must consult with the principal investigator, Andreas Rimner, Doctor of Medicine (MD) * Hepatic impairment defined by ChildPugh class (ChildPugh class B \& C); * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy within 30 days prior to registration, if indicated. Note: HBV viral testing is not required for eligibility for this protocol * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load within 30 days prior to registration * • Active lung infection requiring IV antibiotics * Patients on immunosuppressive therapy, for example history of organ or bone marrow transplant or other hematologic disorders that are expected to compromise life expectancy or tolerance of treatment; * Prior nephrectomy on the contralateral side of MPM * Ipsilateral thoracic electronic implant, e.g. pacemaker, defibrillator, unless switched to the contralateral side prior to initiation of radiation therapy (RT) * Prior thoracic radiation therapy (patients with prior thoracic RT cannot be planned to 50-60 Gy without exceeding normal tissue constraints) * Use of bevacizumab or other antiangiogenic therapy to treat current mesothelioma (due to potential for increased complications from local therapy). * For patients who received neoadjuvant systemic therapy prior to study entry, surgery planned to occur greater than 8 weeks following neoadjuvant systemic therapy PRIOR TO STEP 2 RANDOMIZATION - ALL PATIENTS * Supplemental oxygen use * Third space fluid that cannot be controlled by drainage or insufficient lung expansion after P/D (this prevents targeting the pleura without exceeding normal tissue constraints) * Prior intrapleural therapy (i.e. intrapleural chemotherapy, photodynamic therapy); pleurodesis is permitted * Bulky residual disease in the major fissure preventing pleural IMRT * Patients who have undergone extrapleural pneumonectomy * Patients with active infection that requires systemic I.V. antibiotics, antiviral, or antifungal treatments
healthy Volunteers: false
maximum Age: 80 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
STEP 1: Patients who received allowed neoadjuvant systemic therapy before study entry undergo pleurectomy/decortication (P/D) within 4 to 8 weeks of systemic therapy. Otherwise, patients undergo P/D within 4 weeks of study entry followed within 4 to 8 weeks by four 21-day cycles of pemetrexed and cisplatin or carboplatin on day 1. STEP 2: Patients receive no treatment.
intervention Names
Drug: Carboplatin
Drug: Cisplatin
Procedure: Decortication
Drug: Pemetrexed
Drug: Pemetrexed Disodium
Procedure: Pleurectomy
label
Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)
type
ACTIVE_COMPARATOR
description
STEP 1: Same as Arm 1. STEP 2: Within 4-8 weeks from the end of Step 1 treatment, patients undergo 25-28 fractions of intensity modulated radiation therapy (IMRT) or pencil beam scanning (PBS) proton therapy 5 days/week over 6 weeks.
intervention Names
Drug: Carboplatin
Drug: Cisplatin
Procedure: Decortication
Radiation: Intensity-Modulated Radiation Therapy
Drug: Pemetrexed
Drug: Pemetrexed Disodium
Radiation: Pencil beam scanning proton therapy
Procedure: Pleurectomy
label
Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)
type
EXPERIMENTAL

interventions

arm Group Labels
Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)
Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)
description
Intravenously
name
Carboplatin
other Names
Blastocarb
Carboplat
Carboplatin Hexal
Carboplatino
Carboplatinum
Carbosin
Carbosol
Carbotec
CBDCA
Displata
Ercar
JM-8
type
DRUG
arm Group Labels
Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)
Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)
description
Intravenously
name
Cisplatin
other Names
Abiplatin
Blastolem
Briplatin
CDDP
Cis-diammine-dichloroplatinum
Cis-diamminedichloridoplatinum
Cis-diamminedichloro Platinum (II)
Cis-diamminedichloroplatinum
Cis-dichloroammine Platinum (II)
Cis-platinous Diamine Dichloride
Cis-platinum
Cis-platinum II
type
DRUG
arm Group Labels
Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)
Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)
description
Undergo decortication
name
Decortication
type
PROCEDURE
arm Group Labels
Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)
description
Daily fractions
name
Intensity-Modulated Radiation Therapy
other Names
IMRT
Intensity Modulated RT
Intensity-Modulated Radiotherapy
type
RADIATION
arm Group Labels
Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)
Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)
description
Intravenously
name
Pemetrexed
other Names
MTA
Multitargeted Antifolate
type
DRUG
arm Group Labels
Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)
Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)
description
Intravenously
name
Pemetrexed Disodium
other Names
Alimta
Almita
LY231514
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt
type
DRUG
arm Group Labels
Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)
description
Daily fractions
name
Pencil beam scanning proton therapy
other Names
PBS proton therapy
intensity modulated proton therapy
type
RADIATION
arm Group Labels
Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)
Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)
description
Undergo pleurectomy
name
Pleurectomy
other Names
Excision of Pleura
type
PROCEDURE

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 16
type: ACTUAL

Registered outcome plans (not posted results)

other Outcomes

description
For each subject, the centrally-reviewed clinical staging (based on positron emission tomography, computed tomography and/or magnetic resonance imaging) will be compared with pathologic staging to determine whether it is under-staging (clinical staging is more extensive than pathologic staging), concordant (clinical staging is same as pathologic staging), or upstaging (clinical staging is less extensive than pathologic staging).
measure
Proportion of Patients With Under-staging, Concordant and Upstaging Between Centrally-reviewed Clinical Staging and Pathologic Staging
time Frame
Up to 5 years
description
Gross residual disease and local failure will be analyzed as competing risk data (death without gross residual disease or death without local failure as the respective competing event). Association between radiation dose to gross residual disease and local failure will be evaluated similarly in multivariable analyses using Fine-Gray regression model.
measure
Association Between Radiation Dose to Gross Residual Disease and Local Control
time Frame
Up to 5 years
description
Proportions of R0/R1 and R2 resections, by type of procedures (extended pleurectomy/decortication (P/D), P/D and partial pleurectomy).
measure
Rate of R0/R1 and R2 Resections, by Type of Procedures (Extended Pleurectomy/Decortication (P/D), P/D and Partial Pleurectomy)
time Frame
Up to 5 years

primary Outcomes

description
Overall survival was to be estimated by the Kaplan-Meier method and arms were to be compared using a log-rank test. Analysis was to occur when at least 105 deaths had been reported. Given the small number of participants due to early study closure, only the number of patients last reported to be alive at time of study termination is reported.
measure
Overall Survival (OS)
time Frame
Randomization to the date of death or last follow-up. Maximum follow-up time from randomization was 25 months.

secondary Outcomes

description
Local failure is defined as local enlargement (LE) or local failure (LF) tumor response, marginal failure (MF), or death. LFFS was to be estimated by the Kaplan-Meier method and arms compared by log-rank test. Analysis was to occur when at least 105 deaths had been reported. Given the small number of participants due to early study closure, only the number of patients last reported to be alive without failure at time of study termination is reported, and no statistical testing was done. LE: ≥ 20% increase in the largest diameter (LD) of target lesion from the smallest LD recorded since the treatment start; based on computed tomography (CT) scan. LF: Progression of pleural tumor thickness or appearance of a site of pleural thickness \> 5 mm in the site of treated tumor. MF: The appearance of a new measurable site of pleural tumor \> 5mm within the treated site or enlarging tumor dimensions corresponding to a 20% increase in LD compared to initial appearance on imaging evaluation.
measure
Local-failure-free Survival (LFFS)
time Frame
From randomization to local failure, death, or last follow-up, whichever occurs first. Maximum follow-up was 25 months.
description
Distant failure (DF) is defined as the appearance of cancer deposits characteristic of metastatic dissemination from mesothelioma. DMFS was to be estimated by the Kaplan-Meier method and arms were to be compared using a log-rank test. Analysis was to occur when at least 105 deaths had been reported. Given the small number of participants due to early study closure, only the number of patients last reported to be alive without failure at time of study termination is reported, and no statistical testing was done.
measure
Distant-metastases-free Survival (DMFS)
time Frame
From randomization to distant failure, death, or last follow-up, whichever occurs first. Maximum follow-up was 25 months.
description
Progression is defined as LE, LF, MF, DF, or death. PFS was to be estimated by the Kaplan-Meier method and arms compared by log-rank test. Analysis was to occur when ≥ 105 deaths had been reported. Given the small number of participants due to early study closure, only the number of patients last reported to be alive without progression at study termination is reported, and no statistical testing was done. LE: ≥ 20% increase in the largest diameter (LD) of target lesion from the smallest LD recorded since the treatment start; based on CT scan. LF: Progression of pleural tumor thickness or appearance of a site of pleural thickness \> 5 mm in the site of treated tumor. MF: The appearance of a new measurable site of pleural tumor \> 5mm within the treated site or enlarging tumor dimensions corresponding to a 20% increase in LD compared to initial appearance on imaging evaluation. DF: The appearance of cancer deposits characteristic of metastatic dissemination
measure
Progression-free Survival (PFS)
time Frame
From randomization to first progression, death, or last follow-up, whichever occurs first. Maximum follow-up was 25 months.
description
Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Adverse events reported as possibly, probably, or definitely related to treatment are considered to be treatment-related adverse events.
measure
Number of Patients With Grade 3 or Higher Treatment-related Adverse Event After Randomization
time Frame
From randomization to death or last follow-up. Maximum follow-up time was 25 months.
description
Global Health Status is calculated from two questions on the EORTC QLQ-C30. The question responses range from 1 "very poor" to 7 "excellent" such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best).
measure
Change From Randomization to 9 Months in Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
time Frame
Randomization and 9 months

Full study description

brief Summary: This trial studies how well the addition of targeted radiation therapy to surgery and the usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural mesothelioma. Targeted radiation therapy such as intensity-modulated radiation therapy or pencil beam scanning uses high energy rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving targeted radiation therapy in addition to surgery and chemotherapy may work better than surgery and chemotherapy alone for the treatment of malignant pleural mesothelioma.
detailed Description: PRIMARY OBJECTIVE: I. To detect an improvement in overall survival with the addition of adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) to surgery and chemotherapy compared to surgery and chemotherapy alone. SECONDARY OBJECTIVES: I. To determine local failure-free survival, distant-metastases-free survival, and progression-free survival with the addition of adjuvant hemithoracic IMPRINT to surgery and chemotherapy compared to surgery and chemotherapy alone. II. To evaluate the treatment-related toxicities in both arms per Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0. III. To detect a clinically meaningful 10-point change in global health status mean scores at 9 months after randomization with the addition of adjuvant IMPRINT as compared to surgery and chemotherapy alone. EXPLORATORY OBJECTIVES: I. To evaluate the degree of under-staging, concordant and upstaging between centrally reviewed clinical staging (based on positron emission tomography (PET), computed tomography (CT) and/or magnetic resonance imaging (MRI)) and pathologic staging. II. To identify immunologic and pathologic biomarkers as predictors of response and potential targets for future combination trials. III. To determine the magnitude of radiation dose escalation to gross residual disease based on combined modality imaging and associated local control rates with dose-painting intensity-modulated radiation therapy (IMRT). IV. To determine the rate of R0/R1 and R2 resections, and type of procedures (extended pleurectomy/decortication \[P/D\], P/D and partial pleurectomy). V. To evaluate the trajectory of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-Q30) and lung cancer specific module (LC13) symptoms in patients treated with IMPRINT by comparing the proportion of patients who respond with "quite a bit" or "very much" LC13 symptoms at 9-12 months post-randomization compared to at 3 months post-randomization. VI. To evaluate changes in health-related quality of life, functional domains, and symptoms over time with the addition of adjuvant IMPRINT as compared to surgery and chemotherapy alone. After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for 3 years.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-d35aef5af6d80a307f5c
requested nct id
NCT04158141
primary nct id
NCT04158141
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Malignant+Mesothelioma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
payload sha256
c2ecc444eb7ae0825a1181e6437e32d82d4e9c7d9382b148be3cc8bb78bb54f6
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-d35aef5af6d80a307f5c
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT04158141
occurrences
context exact
NCT04158141
end
11
exact text
NCT04158141
start
0
offset unit
unicode_code_points
query cond
Malignant Mesothelioma
query disease state id
ds-malignant-mesothelioma
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-malignant-mesothelioma-000.json
source file sha256
0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
source json pointer
/studies/32/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
177b9b3ce8608dc9e2f24534e1e60e91762c8bf0269c90bf3e7e5a1dc677320a
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Malignant+Mesothelioma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice